Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00063999 · ClinicalTrials.gov registry record · Phase 3
Doxorubicin Hydrochloride, Cisplatin, and Paclitaxel or Carboplatin and Paclitaxel in Treating Patients With Stage III-IV or Recurrent Endometrial Cancer
A Phase 3 study of Recurrent Uterine Corpus Carcinoma and Stage IIIA Uterine Corpus Cancer AJCC v7, sponsored by GOG Foundation.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,381
- Enrollment target
- 20
- Study locations
NCT00063999 is a Phase 3 study of Recurrent Uterine Corpus Carcinoma and Stage IIIA Uterine Corpus Cancer AJCC v7 that has completed, run by GOG Foundation. The registered enrollment target is 1,381 participants, above the 459-participant average among 7 other Recurrent Uterine Corpus Carcinoma trials with a reported enrollment target (201% higher). The trial reports 20 study locations across 5 states.
The verdict
NCT00063999, a Phase 3 study of Recurrent Uterine Corpus Carcinoma and Stage IIIA Uterine Corpus Cancer AJCC v7, has completed, sponsored by GOG Foundation.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,381 participants
- Enrollment target
- 20
- Study locations
Study Summary
This randomized phase III trial compares how well two different combination chemotherapy regimens (doxorubicin hydrochloride, cisplatin, and paclitaxel versus carboplatin and paclitaxel) work in treating patients with endometrial cancer that is stage III-IV or has come back (recurrent). Drugs used in chemotherapy such as doxorubicin hydrochloride, cisplatin, paclitaxel, and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. It is not yet known which combination chemotherapy regimen is more effective in treating endometrial cancer.
Conditions Studied
Interventions
- DRUG Carboplatin
- DRUG Cisplatin
- OTHER Laboratory Biomarker Analysis
- DRUG Doxorubicin Hydrochloride
- BIOLOGICAL Filgrastim
Study Locations (20)
California
- Providence Saint Joseph Medical Center/Disney Family Cancer Center - Burbank
- John Muir Medical Center-Concord Campus - Concord
- City of Hope Comprehensive Cancer Center - Duarte
- Kaiser Permanente-Fremont - Fremont
- Saint Jude Medical Center - Fullerton
- Marin Cancer Care Inc - Greenbrae
- Long Beach Memorial Medical Center-Todd Cancer Institute - Long Beach
- Kaiser Permanente Los Angeles Medical Center - Los Angeles
- USC / Norris Comprehensive Cancer Center - Los Angeles
- Cedars Sinai Medical Center - Los Angeles
- UCLA / Jonsson Comprehensive Cancer Center - Los Angeles
Alabama
- University of Alabama at Birmingham Cancer Center - Birmingham
- Clearview Cancer Institute - Huntsville
- Mobile Infirmary Medical Center - Mobile
- Providence Hospital - Mobile
Arkansas
- Highlands Oncology Group PA - Fayetteville - Fayetteville
- Washington Regional Medical Center - Fayetteville - Fayetteville
- University of Arkansas for Medical Sciences - Little Rock
Alaska
- Providence Alaska Medical Center - Anchorage
Arizona
- Mayo Clinic in Arizona - Scottsdale
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,381 participants |
| Start Date | 2003-08-25 |
| Est. Completion | 2021-01-05 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00063999
The ClinicalTrials.gov registry entry for NCT00063999 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 1,381 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 459-participant average among 7 other Recurrent Uterine Corpus Carcinoma trials with a reported enrollment target (201% higher). The listed sponsor is GOG Foundation, which has 14 total studies on file at ClinicalTrials.gov.
The record links to 6 conditions, with Recurrent Uterine Corpus Carcinoma appearing as the primary indexed condition, and to 5 interventions - of which Carboplatin is the first listed.
NCT00063999 reports 20 study locations spanning 5 distinct geographic areas - top geographies include California, Alabama, Arkansas.
Frequently Asked Questions
What is clinical trial NCT00063999 about?
NCT00063999 is a clinical study titled "Doxorubicin Hydrochloride, Cisplatin, and Paclitaxel or Carboplatin and Paclitaxel in Treating Patients With Stage III-IV or Recurrent Endometrial Cancer". This randomized phase III trial compares how well two different combination chemotherapy regimens (doxorubicin hydrochloride, cisplatin, and paclitaxel versus carboplatin and paclitaxel) work in treating patients with endometrial cancer that is stage III-IV or has come back (recurrent). Drugs used i...
What is the current status of trial NCT00063999?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,381 participants. The study started on 2003-08-25. Estimated completion is 2021-01-05.
What conditions does trial NCT00063999 study?
This clinical trial studies the following conditions: Recurrent Uterine Corpus Carcinoma, Stage IIIA Uterine Corpus Cancer AJCC v7, Stage IIIB Uterine Corpus Cancer AJCC v7, Stage IIIC Uterine Corpus Cancer AJCC v7, Stage IVA Uterine Corpus Cancer AJCC v7.
What interventions are being tested in trial NCT00063999?
The interventions under investigation include: Carboplatin (DRUG), Cisplatin (DRUG), Laboratory Biomarker Analysis (OTHER), Doxorubicin Hydrochloride (DRUG), Filgrastim (BIOLOGICAL).
Who is sponsoring clinical trial NCT00063999?
This trial is sponsored by GOG Foundation, which has 14 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00063999 being conducted?
This trial has 20 study locations across Alabama, Alaska, Arizona, Arkansas, California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Recurrent Uterine Corpus Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Surgery and Chemotherapy With or Without Chemotherapy After Surgery in Treating Patients With Ovarian, Fallopian Tube, Uterine, or Peritoneal Cancer
ACTIVE NOT RECRUITING · Phase 1
-
Trastuzumab in Treating Patients With Stage III, Stage IV, or Recurrent Endometrial Cancer
COMPLETED · Phase 2
-
Akt Inhibitor MK2206 in Treating Patients With Recurrent or Advanced Endometrial Cancer
COMPLETED · Phase 2
-
Medroxyprogesterone in Treating Patients With Endometrioid Adenocarcinoma of the Uterine Corpus
COMPLETED · Phase 2
-
Biomarkers in Tumor Tissue Samples From Patients With Stage III, Stage IV, or Recurrent Endometrial Cancer
COMPLETED
-
Prognostic Biomarkers in Patients With Endometrial Cancer
COMPLETED
Explore more on PlainTrial
Recurrent Uterine Corpus Carcinoma
All registered trials for this condition
Stage IIIA Uterine Corpus Cancer AJCC v7
All registered trials for this condition
Alabama
All trials with a study site in Alabama
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.